Electronics Mart India IPO

Pre-Apply

About Supriya Lifescience IPO

Supriya Lifescience began as a partnership firm M/s Supriya Chemicals and got incorporated in 2008. Currently, the company is a notable manufacturer of Active Pharmaceuticals Ingredients or API with a niche of 39 products offering solutions to a wide range of therapeutic segments.

The company has a state-of-the-art production facility at Ratnagiri, Maharashtra. Equipped with the latest technology and a strong R&D team, Supriya Lifescience was the largest exporter of Ketamine Hydrochloride (65%-70%) and Chlorpheniramine Maleate (45%-55%) between FY2017 and FY2020.

Supriya Lifescience IPO Objectives

- Meet capital expenditure needs worth Rs. 85.38 crores.
- Repayment or part-payment of their Rs. 67 crore debt.
- Expand its current manufacturing plant at Lote, Maharashtra 

Supriya Lifescience IPO - Details

This IPO will likely consist of Rs. 200 crores worth of fresh issue shares, and the offer for sale will be worth about Rs. 500 crores. The company has allotted 75% of its shares to qualified institutional buyers (QIB), 15% for non-institutional investors (NII), and 10% for retail individual investors (RII).

Opening Date

Dec 16, 2021

Closing Date

Dec 20, 2021

Price Band

₹265 to ₹274

per equity share

Issue Size

₹700.00 Cr

Face Value

₹ 2

per equity share

Market Lot

54 Shares

Opening Date

Dec 16, 2021

Closing Date

Dec 20, 2021

Price Band

₹265 to ₹274

per equity share

Issue Size

₹700.00 Cr

Face Value

₹ 2

per equity share

Market Lot

54 Shares

Listing at NSE, BSE

Supriya Lifescience IPO Important Dates

IPO Open Date Dec 16, 2021
IPO Close Date Dec 20, 2021
Basis Of Allotment Date Dec 23, 2021
Initiation Of Refunds Dec 24, 2021
Credit Of Shares To
Demat ACcount
Dec 27, 2021
IPO Listing Date Dec 28, 2021

Supriya Lifescience IPO Latest News and Subscription Status Today [Live]

At 10:40:00 AM.

- This IPO has been subscribed 7.62x by 10:40 AM. on Day 3

- It is a public issue of 1,45,28,299 equity shares.

 Status of Subscription

- (QIB) Qualified institutional buyers: 0.61x

- (NII) Non-institutional buyers: 5.12x

- (RII) Retail Individual buyers: 32.42x

At 11:40:00 AM.

- This IPO has been subscribed 9.10x by 11:40 AM. on Day 3

- It is a public issue of 1,45,28,299 equity shares.

 Status of Subscription

- (QIB) Qualified institutional buyers: 0.63x

- (NII) Non-institutional buyers: 7.15x

- (RII) Retail Individual buyers: 37.43x

At 12:40:00 PM.

- This IPO has been subscribed 10.06x by 12:40 PM. on Day 3

- It is a public issue of 1,45,28,299 equity shares.

 Status of Subscription

- (QIB) Qualified institutional buyers: 1.04x

- (NII) Non-institutional buyers: 8.29x

- (RII) Retail Individual buyers: 39.77x

At 1:40:00 PM.

- This IPO has been subscribed 25.47x by 1:40 PM. on Day 3

- It is a public issue of 1,45,28,299 equity shares.

 Status of Subscription

- (QIB) Qualified institutional buyers: 4.76x

- (NII) Non-institutional buyers: 55.69x

- (RII) Retail Individual buyers: 42.24x

At 3:10:00 PM.

- This IPO has been subscribed 44.26x by 3:10 PM. on Day 3

- It is a public issue of 1,45,28,299 equity shares.

 Status of Subscription

- (QIB) Qualified institutional buyers: 16.46x

- (NII) Non-institutional buyers: 96.37x

- (RII) Retail Individual buyers: 49.47x

At 4:10:00 PM.

- This IPO has been subscribed 71.28x by 4:10 PM. on Day 3

- It is a public issue of 1,45,28,299 equity shares.

 Status of Subscription

- (QIB) Qualified institutional buyers: 31.83x

- (NII) Non-institutional buyers: 161.22x

- (RII) Retail Individual buyers: 54.75x

At 5:10:00 PM.

- This IPO has been subscribed 71.47x by 5:10 PM. on Day 3

- It is a public issue of 1,45,28,299 equity shares.

 Status of Subscription

- (QIB) Qualified institutional buyers: 31.83x

- (NII) Non-institutional buyers: 161.22x

- (RII) Retail Individual buyers: 55.75x

At 10:40:00 AM.

- This IPO has been subscribed 2.93x by 10:40 AM. on Day 2

- It is a public issue of 1,45,28,299 equity shares.

 Status of Subscription

- (QIB) Qualified institutional buyers: 0.00x

- (NII) Non-institutional buyers: 0.94x

- (RII) Retail Individual buyers: 14.72x

At 11:40:00 AM.

- This IPO has been subscribed 3.17x by 11:40 AM. on Day 2

- It is a public issue of 1,45,28,299 equity shares.

 Status of Subscription

- (QIB) Qualified institutional buyers: 0.00x

- (NII) Non-institutional buyers: 0.97x

- (RII) Retail Individual buyers: 16.00x

At 12:40:00 PM.

- This IPO has been subscribed 3.54x by 12:40 PM. on Day 2

- It is a public issue of 1,45,28,299 equity shares.

 Status of Subscription

- (QIB) Qualified institutional buyers: 0.00x

- (NII) Non-institutional buyers: 1.16x

- (RII) Retail Individual buyers: 17.70x

At 1:40:00 PM.

- This IPO has been subscribed 3.79x by 1:40 PM. on Day 2

- It is a public issue of 1,45,28,299 equity shares.

 Status of Subscription

- (QIB) Qualified institutional buyers: 0.00x

- (NII) Non-institutional buyers: 1.31x

- (RII) Retail Individual buyers: 18.88x

At 2:40:00 PM.

- This IPO has been subscribed 4.27x by 2:40 PM. on Day 2

- It is a public issue of 1,45,28,299 equity shares.

 Status of Subscription

- (QIB) Qualified institutional buyers: 0.00x

- (NII) Non-institutional buyers: 1.89x

- (RII) Retail Individual buyers: 20.64x

At 3:40:00 PM.

- This IPO has been subscribed 4.86x by 3:40 PM. on Day 2

- It is a public issue of 1,45,28,299 equity shares.

 Status of Subscription

- (QIB) Qualified institutional buyers: 0.53x

- (NII) Non-institutional buyers: 2.00x

- (RII) Retail Individual buyers: 22.17x

At 5:10:00 PM.

- This IPO has been subscribed 5.69x by 5:10 PM. on Day 2

- It is a public issue of 1,45,28,299 equity shares.

 Status of Subscription

- (QIB) Qualified institutional buyers: 0.53x

- (NII) Non-institutional buyers: 2.90x

- (RII) Retail Individual buyers: 25.38x

At 10:40:00 AM.

- This IPO has been subscribed 0.64x by 10:40 AM. on Day 1

- It is a public issue of 1,45,28,299 equity shares.

 Status of Subscription

- (QIB) Qualified institutional buyers: 0.00x

- (NII) Non-institutional buyers: 0.37x

- (RII) Retail Individual buyers: 2.98x


At 11:40:00 AM.

- This IPO has been subscribed 1.05x by 11:40 AM. on Day 1

- It is a public issue of 1,45,28,299 equity shares.

 Status of Subscription

- (QIB) Qualified institutional buyers: 0.00x

- (NII) Non-institutional buyers: 0.38x

- (RII) Retail Individual buyers: 5.19x


At 12:40:00 PM.

- This IPO has been subscribed 1.32x by 12:40 PM. on Day 1

- It is a public issue of 1,45,28,299 equity shares.

 Status of Subscription

- (QIB) Qualified institutional buyers: 0.00x

- (NII) Non-institutional buyers: 0.40x

- (RII) Retail Individual buyers: 6.68x

At 2:10:00 PM.

- This IPO has been subscribed 1.60x by 2:10 PM. on Day 1

- It is a public issue of 1,45,28,299 equity shares.

 Status of Subscription

- (QIB) Qualified institutional buyers: 0.00x

- (NII) Non-institutional buyers: 0.43x

- (RII) Retail Individual buyers: 8.15x

At 3:10:00 PM.

- This IPO has been subscribed 1.90x by 3:10 PM. on Day 1

- It is a public issue of 1,45,28,299 equity shares.

 Status of Subscription

- (QIB) Qualified institutional buyers: 0.00x

- (NII) Non-institutional buyers: 0.55x

- (RII) Retail Individual buyers: 9.60x

At 4:10:00 PM.

- This IPO has been subscribed 2.16x by 4:10 PM. on Day 1

- It is a public issue of 1,45,28,299 equity shares.

 Status of Subscription

- (QIB) Qualified institutional buyers: 0.00x

- (NII) Non-institutional buyers: 0.61x

- (RII) Retail Individual buyers: 10.97x

At 5:10:00 PM.

- This IPO has been subscribed 2.33x by 5:10 PM. on Day 1

- It is a public issue of 1,45,28,299 equity shares.

 Status of Subscription

- (QIB) Qualified institutional buyers: 0.00x

- (NII) Non-institutional buyers: 0.66x

- (RII) Retail Individual buyers: 11.84x

Why Should You Invest in Supriya Lifescience IPO?

Supriya Lifescience is one of the prominent speciality chemical manufacturers in this country. Their USP is their exclusive product portfolio paired with a strong R&D team. Following are some reasons to subscribe to its IPO –

1. Moving forward with its listing on BSE and NSE, Supriya Lifescience has a strong financial record with steadily increasing revenue for the past 3 financial years of 2018 to 2020. However, the revenue has dipped in FY2021.

2. The total asset of the company has increased steadily between FY2019 and FY2021.

3. Supriya Lifescience delivered profits for two consecutive fiscals of 2019 – 20 and 2020 – 21. The profit amounts are Rs. 733 million and Rs. 761 million, respectively.

4. Besides its domestic market operations, the company has maintained a steady export volume.

5. Its wide product portfolio comprises more than 30 APIs catering to various pharmaceuticals companies in Asia, Europe, Latin America and North America.

Financial Highlights

Financial Year Total Assets (in crores) Total Revenue (in crores) Profit After Tax (in crores)
2020 – 21 (As of December 2020) Rs. 356.82 crores Rs. 267.93 crores Rs. 76.19 crores
2019 – 20 Rs. 336.4 crores Rs. 322.71 crores Rs. 73.37 crores
2018 – 19 Rs. 253.05 crores Rs. 285.86 crores Rs. 39.42 crores

How to apply for Supriya Lifescience IPO?

You can apply for the Supriya Lifescience IPO in these ways:

UPI
Link your bank account to a reliable UPI ID and register it with your Angel One account. Proceed to book Supriya Lifescience IPO shares using the ID, confirm the payment on the UPI app, and block the amount for allotment.

Demat Account

1. If you are already a client of Angel One, apply directly for Supriya Lifescience IPO, click here.
2. If you’re a new investor Open DEMAT Account for free with Angel One to begin your investment journey.

Supriya Lifescience IPO – Noteworthy Highlights

Incorporated in 2008, Supriya Lifescience has become a market leader in the Active Pharmaceuticals Ingredients (API). Here are some highlights about the company that potential investors can take note of –

1. The company has an EU-GMP, and USA-FDA approved facility in Ratnagiri.

2. Supriya Lifescience is a pioneer in therapeutic segments such as Anti-allergic vitamins, anti-histamine, and anti-asthmatic.

3. Moreover, the product portfolio contains more than 30 APIs, targeting segments like analgesic, different vitamins, anaesthetic, anti-asthmatic, anti-allergic, and anti-histamine.

4. Supriya Lifesciences was the most significant Indian exporter of Ketamine Hydrochloride (65%-70%) and Chlorpheniramine Maleate (45%-55%) between FY2017 and 2020.

5. It has exported APIs to 78 countries and 286 distributors. The majority overseas client base of the company is in Asia, Europe, North America, and Latin America.

6. Some of Supriya Lifescience’s top customers include American International Chemical Inc, Suan Farma Inc, Akum Drugs Ltd, Mankind Pharma Ltd, and Syntec Do Brasil LTDA.

Supriya Lifescience IPO – SWOT Analysis

strengths

Strengths

  • Varied Product Portfolio: Supriya Lifescience has a diverse product portfolio buoyed by a leading R&D team. The company has more than 30 APIs.
  • Global Presence: Supriya Lifescience operates in more than 105 countries in North America, Latin America, Asia, and Europe.
  • Strong Finances: The company has a robust financial base with profits in back-to-back financial years of 2020 and 2021.
Weaknesses

Weaknesses

  • Dependency on Export: Supriya Lifescience’s revenue depends largely on exports; hence, any new export regulations can hurt the company.
Opportunities

Opportunities

  • High Potential of the Indian Chemical Market: The Indian chemical market is estimated to reach a valuation of $326 billion by 2025 at a CAGR of 12%, and the speciality chemical industry accounts for 47% of this segment. Moreover, the domestic speciality chemical market is likely to register a CAGR of 11% to 12% during the same period. Thus, Supriya Lifescience will be firmly positioned with the IPO proceeds to leverage their growth.
Threats

Threats

  • Existing Competition: Supriya Lifescience is operating in a highly competitive segment against established and emerging market peers.
Strenghts Strengths
Weaknesses Weaknesses
Opportunities Opportunities
Threats Threats

Strengths

  • Brand recognition: The company has a global footprint in more than 24 countries with a partnered network of over 1.5 million restaurants.
  • Business model: Zomato follows a B2C business model that connects customers to a wide network of restaurants. The company has an asset-less business model, giving it high financial leverage.
  • Marketing: Zomato follows a robustly creative marketing strategy both online and offline. Accordingly, it has a decent customer engagement and has over 11.2 million active users each month.
  • User-friendly: The Zomato app and web portal come with an easy-to-navigate UI.

Weaknesses 

  • Competition: Newer food delivery platforms with unique offerings are mushrooming now more than ever. It not only limits Zomato’s market expansion scope but also imposes a threat to its existing customer base.
  • Business model: Though Zomato’s business model is currently working in its favour, there are high chances tech developments could impose a foundational threat. If Zomato stops innovating and improving its customer service, its very successful business model could restrain its potential.

Opportunities 

  • Market expansion: Zomato is active in 25 countries. Moreover, it has not reached the saturation point yet. Therefore, given its current market momentum and growth potential, it can be expected that the food delivery service will witness upward mobility and rapid market expansion in the next couple of years.
  • Online users: The percentage of smartphones users with interest access is increasing every day. This opens up a great growth opportunity for Zomato to expand its target base and market presence.
  • Technological development: As the tech space continues to bring in newer innovations, it could open newer paths for Zomato to explore.

Threats 

  • Competition: Newer food delivery platforms with unique offerings are mushrooming now more than ever. It not only limits Zomato’s market expansion scope but also imposes a threat to its existing customer base.
  • Business model: Though Zomato’s business model is currently working in its favour, there are high chances tech developments could impose a foundational threat. If Zomato stops innovating and improving its customer service, its very successful business model could restrain its potential.

Competitive Analysis: Market Peers

Following is an overview of how their listed market peers are performing as of 27 July 2021 –

Competitor Sector P/E Market Cap. (in INR and crores) Dividend yield
Solara Active Pharma Sciences Ltd. 40.48 6,215 0.41
Neuland Laboratories Ltd 40.48 2,618 0.25
Aarti Drugs Ltd 40.48 6,672 0.35
Wanbury Ltd 40.48 282 NA
Divis Laboratories Ltd 40.48 1,27,196 0.42
RPG Life Sciences Ltd 40.48 834 1.43
ANG Lifesciences India Ltd 132.46 141 NA
** Note: Market cap is mentioned in crores

Supriya Lifescience IPO FAQs

What is Supriya Lifescience IPO?

Supriya Lifescience’s Rs. 1200 crore-IPO includes fresh issue of shares worth Rs. 200 crores and OFS of up to Rs. 1000 crores as specified in the DRHP.

When is Supriya Lifescience IPO's listing date?

The listing date of Supriya Lifescience IPO hasn’t been disclosed yet.

What will be the price band of Supriya Lifescience IPO?

Any information regarding the IPO price band for Supriya Lifescience is not available yet.

What is the minimum lot size that retail investors can subscribe to?

Any updates on the minimum lot size for Supriya Lifescience IPO is not available yet. 

Who are the merchant bankers to the Supriya Lifescience IPO?

Axis Capital Limited and ICICI Securities are the merchant bankers to this IPO.

Who is the registrar for Supriya Lifescience IPO?

Link Intime India Private Limited is the registrar appointed for Supriya Lifescience IPO.

Which categories of investors are allowed to participate in this IPO?

Retail individual investors, non-institutional investors, and qualified institutional buyers are the categories of investors who will participate in this initial public offering.

What is the application process for the Supriya Lifescience IPO via the Angel One App?

To apply for this IPO of Supriya Lifescience, follow the below-mentioned steps –
Step 1: Navigate to the ‘investment opportunities’ section on the Angel One mobile app
Step 2: Visit the ‘IPOs and FPOs’ option and provide the required details
Step 3: Enter your NPCI approved UPI handle
Step 4: Click on ‘invest’ and submit your bid for this Supriya Lifescience IPO

Is it possible to apply for Supriya Lifescience IPO without a UPI ID?

Yes, it is possible to apply for Supriya Lifescience IPO without a UPI ID. But, in that case, you need to use the ASBA process extended by a bank. Also, if you do not have a UPI ID, you can generate one without any hassle. Simply refer to the UPI handles approved and specified on the NPCI list.

What is the process of generating a UPI ID using the BHIM app?

You can generate a UPI ID using the BHIM by following the below-mentioned steps –
Step 1: Download and install the BHIM UPI app on your smartphone
Step 2: Validate your mobile number and create a PIN or password needed to operate this app
Step 3: Select a bank from the list of financial institutions mentioned in NPCI’s approved list
Step 4: This BHIM UPI app will then collect your bank account information automatically
Step 5: In case you have multiple bank accounts, select one that you want to register and connect with this app
Step 6: Set up a personal UPI ID for security reasons
You can then see your UPI ID later in the ‘Profile’ section of this app.

How to accept a mandate request for Supriya Lifescience IPO?

You can accept the mandate request of Supriya Lifescience IPO by using a UPI app. To learn how this process works, and access a step-by-step guide, click here.

Is it compulsory to accept a UPI mandate request instantly?

Yes, it is vital to accept a UPI mandate request once you get it. Nevertheless, the window of sanction stays open from the closing bell of the previous working day to 12 noon of the next working day.

How fast can I expect to get a UPI mandate request after applying for this Supriya Lifescience IPO?

You can receive a UPI mandate request within 15 to 20 minutes of placing your bid for Supriya Lifescience IPO. However, this process can get delayed due to different reasons.

I have accepted the IPO mandate request of Supriya Lifescience; but, its status on the Angel One app is still showing pending. So, what can I do now?

The Angel One app does not display real time updates for UPI mandate requests. Hence, you see the pending status. Nonetheless, if you have accepted this UPI mandate request, you can find the updated status in the order book of the IPO you are applying for.

I am unable to locate my UPI ID in the dropdown menu of the Angel One App when applying for Supriya Lifescience IPO. What is the reason?

In case you cannot find your UPI ID in this dropdown menu, it means that your existing UPI ID is not NPCI approved. In that case, you can simply generate a substitute one using any UPI handle approved and mentioned under the NPCI List.

I cannot apply for Supriya Lifescience IPO through my current UPI handle. What can be the reason?

If you want to apply for Supriya Lifescience IPO, you can only do it through UPI handles that has NPCI’s approval. However, if you cannot do so, you can refer to the list of apps that have NPCI’s approval to extend UPI service and then register with any of them to apply for this IPO.

What is a cut-off price? Is it possible to apply at this price point?

The cut-off price is a price point at which shares of Supriya Lifescience and shares of other companies will be listed on the bourses. This is a pre-set price and is determined during the allotment stage of an IPO. Also, if you apply at this price point, it suggests that you are willing to bid for Supriya Lifescience IPO at this price point. Moreover, applying at a cut-off price also improves your chance of securing an allotment.

Can I use a bank account not connected with the Angel One app to apply for Supriya Lifescience IPO?

Yes, you can apply for Supriya Lifescience IPO using a bank account not connected with the Angel One App. However, this account must be in your name.

Can I utilise my minor daughter’s bank account to bid for Supriya Lifescience IPO?

No, you cannot utilise your minor daughter’s bank account to apply for Supriya Lifescience IPO or any other public issues. Also, the Angel One App has no guidelines regarding this, where you can use your minor daughter’s bank account to apply for IPOs. However, a minor can easily submit a bid for a public offer using the ASBA process through a bank.

Can I use current accounts to apply for the IPO of Supriya Lifescience?

No, you cannot use current accounts to apply for the public issue of Supriya Lifescience. Banks do not approve any IPO application, be it Supriya Lifescience or any other made via current accounts. Hence, it is ideal to apply for IPOs through savings accounts. Also, you can talk to your respective banks for further details.

Can I use my Hindu Undivided Family account to apply for the Supriya Lifescience IPO? 

No, it is not possible to use a Hindu Undivided Family account to submit a bid for any IPOs via Angel One platform. However, if you apply via the ASBA process specified by banks, then you can take the assistance of this account.

Can I submit multiple bids for the initial public offering of Supriya Lifescience using a single PAN?

No, you cannot submit multiple IPO bids use one PAN, be it for Supriya Lifescience or any other. The reason behind this is, if you submit multiple bids for an IPO using a single PAN, you will not get approval for your IPO. Thus, you will also fail to receive allotment against it.

Is it possible to change my bid for the Supriya Lifescience IPO after confirming the final application?

Yes, it is possible to change the lot size and the UPI ID of your Supriya Lifescience IPO, even after confirming your bid for it. However, remember that any changes that your make will be counted as a new bid once you approve the UPI mandate request. In such cases, the banks will block the required funds once more, besides your current application. Additionally, you will get a fresh UPI mandate request for this new bid, just like before.

Can NRIs submit bids for Supriya Lifescience IPO using the Angel One App?

No, NRIs cannot use the Angel One app to apply for Supriya Lifescience IPO. However, they can always take the assistance of the ASBA process (Application Supported by Blocked Amount) via their respective banks to try and secure allotment of this IPO.

What are the probable reasons behind my IPO application of Supriya Lifescience getting rejected?

Likely reasons for your Supriya Lifescience IPO application getting rejected can be –
● Providing an incorrect UPI PIN while approving a UPI mandate
● Unable to ensure that your UPI ID, bank account, and Demat account are linked with the same PAN
For example, in case you use your friend’s UPI ID to make payment and personal Demat account to apply for this public issue. In that case, your application can get rejected –
● If your PAN and your friend’s UPI ID are not linked
● If your Demat account is not connected with your friend’s bank account

I have completed the application for Supriya Lifescience IPO, but the funds are not debited yet. What is the reason?

A point you should remember here is that banks do not debit funds required for an IPO subscription right after you submit the application. But, they will freeze the due amount, and once you get this allotment, they will debit the required funds. Whereas, if you cannot secure the allotment or your UPI mandate request expires, they will release these funds.

How to get assured allotment of Supriya Lifescience IPO?

It is impossible to provide assurance regarding the allotment of any IPO you decide to go ahead with. In the cases of oversubscription, which is quite common, shares are allocated using a lottery system. Hence, it is possible to guarantee and allotment of any IPO.
However, you should keep in mind that the Angel One platform only allows you to apply for a public issue, but, it does not offer any assurance regarding allotment. However, you can better your chances by following some tips –
● Using a Demat Account linked with your PAN
● Applying at the cut-off price
● Confirm that your bank account and UPI ID are linked through a single PAN, and failing to keep that can lead to rejection.
For instance, person X has applied for the Shriram Properties IPO via his Demat Account but person Y’s UPI ID. In such cases, the application can get rejected due to –
● Person Y’s UPI ID is not linked with X’s PAN
● Person X’s Demat account is not linked with Y’s bank account

Do I need to bear any additional fees to apply for the Supriya Lifescience IPO?

No, you need not to bear any extra charges to apply for any IPO using the Angel One app or platform.

What is the estimated time necessary to block or unblock the funds of an IPO subscription?

After approving a UPI mandate request, the funds required for that public issue will be blocked. However, these funds will be released only if you fail to get an IPO allotment, or the UPI mandate expires. But, if the funds are not unblocked even after these two scenarios, contact your bank for clarification.

How to locate my UPI ID in the Angel One mobile app?

You can find your UPI ID in the ‘profile’ section of any UPI app. In addition, you can click here to learn about this procedure in lengths, and how to access it across different apps.

Enjoy Zero Brokerage on
Equity Delivery

Enjoy Zero Brokerage on Equity Delivery

Get the link to download the App

Send App Link